Latest News and Press Releases

TEL AVIV, Israel, May 13, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, May 12, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class...

TEL AVIV, Israel, May 5, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class...

TEL AVIV, Israel, April 29, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class...

-Will host conference call at 8:30 am ET today- -Also announced positive top-line interim results for Phase 2b trial testing VB-111 in recurrent glioblastoma- TEL AVIV, Israel, March 25, 2015...

TEL AVIV, Israel, March 25, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, March 19, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...

TEL AVIV, Israel, March 4, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) a clinical-stage biotechnology company committed to the discovery, development and commercialization of...

TEL AVIV, Israel, Feb. 17, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) a clinical-stage biotechnology company committed to the discovery, development and commercialization of...

-- Phase 2 Studies of VB-201 in Patients with Psoriasis and Ulcerative Colitis Did Not Meet Primary Endpoints -- -- Company to Continue Focus on VB-111 Development in rGBM with Phase 3 to Initiate...